Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
Agilent Technologies has launched the Agilent 9500 Triple Quadrupole ICP-MS, a new inductively coupled plasma mass spectrometry system designed to simplify the transition for laboratories from single to triple quadrupole technology for advanced trace elemental analysis. This system aims to improve productivity, streamline interference removal, and provide high-quality data more easily, addressing challenges faced by labs with increasing testing demands and limited skilled resources. The 9500 ICP-MS offers faster data acquisition, reduced costs, and enhanced interference removal, making advanced analysis more accessible for various applications including environmental, food, and pharmaceutical testing.
Baird Adjusts Agilent Technologies Price Target to $156 From $155, Maintains Outperform Rating
Baird has raised its price target for Agilent Technologies (A) to $156 from $155, while maintaining an "Outperform" rating on the stock. This adjustment comes as Agilent Technologies continues its quarterly dividend historically at $0.255 per share, and other related news. Agilent specializes in measurement instruments for various sectors including life sciences and electronics.
Agilent launches 9500 triple quadrupole ICP-MS system
Agilent Technologies Inc. (NYSE:A) has launched its new 9500 Triple Quadrupole ICP-MS system, designed for trace elemental analysis and aimed at laboratories transitioning to triple quadrupole technology. This system offers improved productivity and lower operational costs, featuring Air Cell and Advanced Helium Mode capabilities, and a significant reduction in acquisition time. Agilent, with a market cap of $32.4 billion, appears undervalued according to InvestingPro analysis, despite trading near its 52-week low.
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
Agilent Technologies Inc. (NYSE: A) has launched its new 9500 Triple Quadrupole ICP-MS system, designed to simplify the transition for laboratories from single quadrupole to advanced triple quadrupole technology for trace elemental analysis. The system aims to improve productivity and provide faster, more accurate results through innovations like Air Cell and advanced Helium Mode, reducing analysis time and operational complexity. This development addresses the growing demand for sophisticated elemental analysis while minimizing the burden on labs with limited skilled resources.
Agilent and Singapore’s NATi sign research partnership on oligonucleotide therapeutics
Agilent Technologies Inc. has partnered with Singapore's Nucleic Acid Therapeutics Initiative (NATi) for a two-year research collaboration focusing on oligonucleotide therapeutics. The partnership aims to accelerate the development of next-generation therapies, particularly ligand-conjugated oligonucleotides, to improve drug delivery beyond the liver and expand treatment options for various diseases. Agilent will provide analytical technologies while NATi contributes expertise in nucleic acid and chemical modifications, with the goal of improving characterization, purification, and quality assessment of lipid-modified oligonucleotides for faster preclinical development.
Agilent inaugurates new biopharma research hub at Chungnam National University in South Korea
Agilent Technologies Inc. has launched a new Open-Biopharma Research Hub (ORCA) at Chungnam National University in South Korea, aiming to enhance the country's biopharma innovation landscape. This state-of-the-art facility will serve as a collaborative platform for academia, R&D organizations, and manufacturers, offering open access to Agilent's advanced R&D systems and fostering talent development through internships and technical mentorship. The initiative reinforces Agilent's commitment to supporting South Korea's growth as a major biomedical R&D and manufacturing hub.
Agilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed
Agilent Technologies Inc. has launched the 1290 Infinity III Fluorescence Detector (FLD), specifically designed for modern ultra-high-performance liquid chromatography (UHPLC) workflows. This new detector offers exceptional sensitivity and UHPLC-ready chromatographic performance, aiming to provide laboratories with improved analytical evidence and confidence in trace-level analysis. It addresses the limitations of traditional detectors by preserving narrow UHPLC peak integrity and delivering rich spectral information, making it suitable for applications in biopharmaceutical analysis, food safety testing, and environmental monitoring.
Agilent and Singapore’s NATi sign research partnership on Oligo
Agilent Technologies Inc. and Singapore's Nucleic Acid Therapeutics Initiative (NATi) have entered a two-year research collaboration to advance next-generation oligonucleotide therapeutics. The partnership will focus on analytical and preparative workflows for ligand-conjugated oligonucleotides to improve drug delivery beyond the liver and expand treatment options for various diseases. This collaboration combines NATi's expertise in nucleic acid and chemical modifications with Agilent's advanced analytical technologies, aiming to accelerate preclinical development in the oligonucleotide therapeutics market, which is projected to reach $18 billion by 2030.
Agilent Technologies (NYSE: A) SVP receives 8,872 restricted stock units award
Agilent Technologies' Senior Vice President, Michael Steven Buckner, was granted 8,872 restricted stock units under the company's 2018 Stock Plan. These units, valued at $0.00 per unit, will vest in four equal annual installments starting May 19, 2027. Following this award, Buckner directly holds 8,887 shares of Agilent common stock.
Should TSA’s FIFA World Cup Screening Deal Prompt a Rethink of Agilent Technologies’ (A) Security Ambitions?
Agilent Technologies Inc. secured a contract with the TSA to deploy its Bulk Alarm Resolution Technology at FIFA World Cup host city airports in the U.S., leveraging its spectroscopy and algorithms for enhanced checkpoint screening. This deal, while showcasing Agilent's technology beyond the lab, does not significantly alter its near-term focus on core pharma, chemicals, and regulatory testing demand, nor does it mitigate risks from tariffs and input costs. The company's diverse applications in security and precision medicine, alongside projected revenue growth, suggest a strong investment narrative, though potential tariff-related cost inflation remains a concern.
Should TSA’s FIFA World Cup Screening Deal Prompt a Rethink of Agilent Technologies’ (A) Security Ambitions?
Agilent Technologies Inc. secured a contract with the U.S. Transportation Security Administration (TSA) to deploy its Bulk Alarm Resolution Technology at FIFA World Cup host city airports, showcasing its R&D capabilities beyond traditional lab settings. While this highlights the versatility of Agilent's technology in high-stakes aviation security, the article suggests it doesn't immediately alter the company's core focus on pharma, chemicals, and regulatory testing demand. The company's future growth and investment narrative, projecting $8.6 billion revenue by 2029, still heavily rely on its core business, alongside emerging opportunities in precision medicine and the ongoing challenge of tariff-driven costs.
New Agilent detector finds trace chemicals in drugs, food and water
Agilent Technologies Inc. has launched the 1290 Infinity III Fluorescence Detector (FLD), designed for modern ultra-high-performance liquid chromatography (UHPLC) workflows. This new detector offers ultra-trace sensitivity and UHPLC-ready performance, enabling confident decision-making in trace-level analysis for applications like biopharmaceutical analysis, food safety testing, and environmental monitoring. It addresses the limitations of traditional fluorescence detectors by optimizing for UHPLC workflows, allowing for faster method development and easier interpretation of complex samples.
Agilent Technologies stock (US00846U1016): Dividend hike follows mixed quarterly update
Agilent Technologies announced a quarterly dividend increase to 25.5 cents per share, which serves as a new catalyst for investors despite mixed quarterly results and updated guidance. The company, a key supplier of analytical instruments and diagnostics for various industries, faces investor scrutiny regarding demand trends in China and pharmaceutical labs. While the dividend increase is a positive signal for income, the stock's future performance largely depends on consistent growth across its segments and the broader recovery of end-markets.
Agilent Technologies Keeps Quarterly Dividend at $0.255 per Share, Payable July 22 to Holders of Record June 30
Agilent Technologies has declared a quarterly dividend of $0.255 per share, maintaining its previous payout. The dividend is scheduled to be paid on July 22 to shareholders of record as of June 30. This announcement indicates the company's consistent dividend policy.
Agilent and Singapore's NATi partner to advance lipid-conjugated oligonucleotide research
Agilent Technologies Inc. has announced a two-year research collaboration with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to advance research into complex oligonucleotide (oligo) candidates. This partnership aims to develop analytical and preparative workflows for ligand-conjugated strategies, extending oligo delivery beyond liver tissues to address a broader range of diseases. The collaboration leverages NATi's expertise and Agilent's advanced analytical instrumentation to accelerate preclinical development of lipid-modified oligos.
Press Release: Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies announced a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is payable on July 24, 2026, to shareholders of record as of the close of business on July 1, 2026. This marks the latest in a series of consistent dividend payments by the company.
25.5-cent Agilent dividend set for July 22, 2026 payout to shareholders
Agilent Technologies Inc. announced a quarterly dividend of 25.5 cents per share of common stock. This dividend will be paid on July 22, 2026, to shareholders recorded as of June 30, 2026. Agilent is a global leader in analytical and clinical laboratory technologies, generating $6.95 billion in fiscal year 2025.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. announced a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on July 22, 2026, to shareholders of record as of June 30, 2026. The company also notes that future dividend timing and amounts are subject to board approval.
Agilent Technologies Inc. stock outperforms competitors on strong trading day
Agilent Technologies Inc. (A) saw its stock increase by 2.90% to $113.78 on a strong trading day, outpacing the S&P 500 Index and the Dow Jones Industrial Average. Despite this gain, the company's stock remains 29.01% below its 52-week high of $160.27, which was achieved on November 25th. The article highlights Agilent's performance within a generally favorable market environment.
Agilent and Singapore's NATi partner to advance lipid-conjugated oligonucleotide research
Agilent Technologies Inc. has announced a two-year research collaboration with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to advance research into lipid-conjugated oligonucleotide candidates. This partnership aims to expand the delivery of oligonucleotide therapies beyond liver tissues to extrahepatic tissues, unlocking new therapeutic applications. The collaboration will leverage NATi's expertise and Agilent's analytical technologies for precise characterization and purification of lipid-modified oligos.
Agilent and Singapore's NATi partner to advance lipid-conjugated oligonucleotide research
Agilent Technologies Inc. and Singapore's Nucleic Acid Therapeutics Initiative (NATi) have announced a two-year research collaboration. This partnership aims to advance lipid-conjugated oligonucleotide research, focusing on developing analytical and preparative workflows for ligand-conjugated strategies to extend oligo delivery beyond liver tissues. Their goal is to unlock access to extrahepatic tissues and expand the therapeutic market for oligonucleotide candidates, which show promise for various diseases.
Agilent Technologies shares may move 5.2% on earnings release
Agilent Technologies (NYSE:A) shares could see a 5.2% movement following its earnings release on May 27, according to options data. The options market has a strong track record of predicting the stock's post-earnings performance, accurately forecasting either the direction or magnitude in six of the last eight quarters. While some significant deviations have occurred, most movements have remained within the anticipated range.
Agilent Technologies Inc. stock (US00846U1016): shares move after quarterly results and guidance upd
Agilent Technologies Inc. (US00846U1016) shares reacted to its Q2 2025 results and updated guidance, which indicated ongoing softness in some life science markets but resilient profitability. The company operates in life sciences tools and diagnostics, providing instruments, consumables, software, and services globally. Agilent revised its full-year fiscal 2025 outlook, narrowing guidance ranges and anticipating a gradual recovery in customer spending later in the year, influencing moderate stock volatility.
Agilent & Singapore Target New Disease Frontiers with Gene Therapy Tech
Agilent Technologies and Singapore's Nucleic Acid Therapeutics Initiative (NATi) have partnered in a two-year research collaboration to advance gene therapy. Their focus is on developing analytical methods for lipid-conjugated oligonucleotides to deliver therapies beyond the liver, addressing a critical bottleneck in the expanding $7 billion oligonucleotide therapeutics market. This alliance leverages Agilent's analytical instrumentation and NATi's expertise to build foundational tools for a new generation of precision medicines, bolstering Singapore's biomedical ambitions.
Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research
Agilent Technologies Inc. and Singapore's Nucleic Acid Therapeutics Initiative (NATi) have announced a two-year research collaboration to advance lipid-conjugated oligonucleotide research. This partnership aims to develop analytical and preparative workflows to support new delivery platforms, extending oligo delivery beyond liver tissues to unlock access to extrahepatic tissues. The collaboration is expected to accelerate preclinical development of next-generation oligo therapeutics and strengthen Singapore's position as a biomedical innovation hub.
Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research
Agilent Technologies Inc. announced a two-year research collaboration agreement with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to advance research into lipid-conjugated oligonucleotide candidates, a field poised to expand precision therapeutics beyond liver-targeted delivery. This partnership aims to develop advanced analytical and preparative workflows, enabling preclinical development for a broader range of diseases and strengthening Singapore's position in biomedical innovation. The collaboration leverages Agilent's instruments and NATi's expertise to accelerate the characterization and purification of these novel therapeutics.
Agilent Technologies Inc. stock (US00846U1016): TSA World Cup contract puts airport security business in focus
Agilent Technologies Inc. has secured a contract with the US Transportation Security Administration (TSA) to provide next-generation bulk alarm resolution technology for airport security ahead of the 2026 FIFA World Cup. This deal showcases Agilent's expansion beyond its traditional lab and diagnostics core into security screening, leveraging its expertise in detection and data analysis. The contract, alongside the planned acquisition of Biocare Medical, highlights the company's continuous strategy to strengthen specialized niches for long-term growth and diversify its revenue streams.
Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors
Agilent Technologies Inc. (A) stock fell 1.37% on Tuesday, closing at $110.57, while the broader market also experienced a downturn. The S&P 500 Index and Dow Jones Industrial Average both declined. The company's stock is currently 31.01% below its 52-week high reached on November 25th.
Agilent Technologies Secures TSA Contract to Supply Airport Security Screening Systems
Agilent Technologies has secured a contract with the Transportation Security Administration (TSA) to supply airport security screening systems. This agreement highlights Agilent's role in enhancing national security through its advanced technology. The systems are designed to improve the efficiency and accuracy of security checks at airports.
Agilent Wins TSA Contract To Upgrade US Airport Security Ahead Of FIFA World Cup 2026
Agilent Technologies has secured a contract with the Transportation Security Administration (TSA) to deploy its Bulk Alarm Resolution Technology (BRT) at US airport security checkpoints. This initiative aims to enhance screening efficiency for liquids, powders, and solids, particularly in FIFA World Cup host cities, to manage the anticipated surge in passenger traffic for the 2026 tournament. The BRT system uses Surface Offset Raman Spectroscopy (SORS) and advanced software for faster and more accurate alarm resolution.
New Agilent scanners to speed liquid checks at U.S. World Cup airports
Agilent Technologies (NYSE: A) has secured a contract with the Transportation Security Administration (TSA) to deploy its new Bulk Alarm Resolution Technology (BRT) at U.S. airports hosting FIFA World Cup matches. This technology uses Surface Offset Raman Spectroscopy (SORS) and advanced algorithms to rapidly and accurately screen liquids, powders, and solids in various containers, aiming to enhance security and improve operational efficiencies at checkpoints. The initiative will help expedite security screening of commonly surrendered items, contributing to a smoother travel experience for passengers.
Susquehanna Issues Positive Forecast for Keysight Technologies (NYSE:KEYS) Stock Price
Susquehanna has increased its price target for Keysight Technologies (NYSE:KEYS) to $415 from $300, maintaining a "positive" rating and suggesting an 18.7% upside. This positive outlook is supported by recent earnings beats, strong revenue growth, and multiple analyst upgrades including from Zacks and Bank of America. Despite some insider selling, institutional ownership remains high, indicating continued confidence in the company.
Keysight Technologies stock (US49338L1035): strong earnings and guidance keep momentum in focus
Keysight Technologies has reported better-than-expected quarterly results and provided upbeat guidance, driving its stock to new highs. The company, a specialist in electronic test and measurement equipment, saw double-digit revenue growth and beat analyst expectations on both sales and earnings. Its strong performance is attributed to continuous innovation in high-growth areas like 5G, data centers, automotive electronics, and aerospace systems.
Agilent Technologies Inc. stock (US00846U1016): earnings miss and cautious outlook keep sentiment su
Agilent Technologies Inc. recently reported lower-than-expected quarterly results and trimmed its full-year outlook, leading to subdued stock performance. The life science tools specialist faces challenges from softer demand in the pharma and chemical sectors. Despite near-term headwinds, Agilent continues to invest in new products for biopharma analytics and cell analysis tools, aiming for long-term growth in these critical areas.
Waters Corporation stock (US9418481035): chromatography specialist in focus after latest quarterly results
Waters Corporation, a US-based specialist in analytical instruments and chromatography systems, is in focus after releasing its latest quarterly figures and updating its outlook for 2026. The article details the company's core business model, key revenue drivers, and competitive position within the life science tools industry. It also explains why Waters Corporation is relevant for US investors seeking exposure to the pharmaceutical and biotechnology sectors.
Convergence Investment Partners LLC Takes $1.88 Million Position in Keysight Technologies Inc. $KEYS
Convergence Investment Partners LLC has initiated a new position in Keysight Technologies Inc. (NYSE:KEYS), purchasing 9,228 shares valued at approximately $1.88 million during the fourth quarter. This move comes as institutional ownership in Keysight remains high, with several major firms increasing their stakes, and the company recently reported stronger-than-expected quarterly earnings. Analysts currently rate Keysight a "Moderate Buy" with a consensus price target of $322.83.
Agilent Technologies opens new Chicopee manufacturing facility
Agilent Technologies has opened a new 85,000-square-foot manufacturing facility in Chicopee, expanding its global operations and three-folding its previous facility size. The company, which purchased the new building in 2022, invested $33 million and plans to add 40 new jobs, with leaders emphasizing the investment in the future and the local community's culture. This expansion aims to enhance supply chain resiliency and manufacturing capabilities for life sciences, diagnostics, and chemical analysis.
Agilent invests $40M to double Massachusetts manufacturing site
Agilent Technologies is investing $40 million to double the size of its manufacturing facility in Chicopee, Massachusetts. This expansion will significantly increase the company's operational footprint in the state. The move is part of the company's capital investment strategy.
Agilent Technologies Inc. stock outperforms competitors despite losses on the day
Agilent Technologies Inc. (A) stock fell by 1.38% to $111.70 on Friday, despite outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average, which also experienced significant losses. The company's stock closed 30.31% below its 52-week high of $160.27, which was reached on November 25th.
Agilent Technologies Inc. stock (US00846U1016): Q1 2026 earnings miss by a cent as guidance points to steady growth
Agilent Technologies Inc. reported a Q1 2026 earnings miss by one cent, with adjusted EPS at $1.36 and revenue of $1.80 billion, slightly below analyst expectations. Despite this, the company projects continued growth, with Q2 2026 guidance aligning with forecasts and a 7% year-over-year revenue increase. The company's diverse business model in life science tools and diagnostics, regular dividends, and expected double-digit EPS growth underscore its appeal to US investors.
Agilent Technologies Inc. stock (US00846U1016): Q1 2026 earnings miss by a hair while revenue rises
Agilent Technologies Inc. reported a Q1 2026 earnings per share of $1.36, narrowly missing the consensus estimate of $1.37, while revenue rose 7% year-over-year to $1.80 billion, slightly below expectations. Despite the slight earnings miss, the company provided Q2 2026 guidance broadly in line with analyst expectations and anticipates continued earnings growth over the next year. The stock has shown modest short-term gains, with investors maintaining a growth premium for the company in the life science tools sector.
Global company Agilent Technologies opens new Chicopee site
Agilent Technologies, a global company, has opened a new facility in Chicopee, Massachusetts. The ribbon-cutting ceremony highlighted the organization's investment in advanced manufacturing and innovation within the community. Agilent Technologies is known for providing cutting-edge instruments, software, and services to various sectors.
Keysight Technologies stock (US49338L1035): Shares gain 0.51% amid Q2 earnings anticipation
Keysight Technologies stock saw a 0.51% increase, closing at $166.45, with higher trading volume ahead of its Q2 earnings report. Analysts project a "moderate buy" rating with a target price of $187.38, anticipating revenue growth. The company, a key player in electronics testing for industries like 5G and automotive, is positioned strongly due to its R&D investments and leadership in software-centric solutions.
Agilent Technologies stock (US00846U1016): Recent patent ruling and market updates
Agilent Technologies is facing market volatility and recent legal challenges, specifically a patent ruling discussed in *Agilent Technologies, Inc. v. Synthego Corp.* Its market capitalization recently adjusted to $31.86 billion. Despite these factors, the company maintains a strong position in the life sciences and diagnostics sectors, supported by its core business model and innovation in analytical instruments.
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V
Worldwide Market Reports has released an in-depth study on the Bioinformatics Platforms Market, forecasting its size and trends from 2026-2033. The report, based on primary interviews and secondary data, analyzes growth drivers, opportunities, risks, and challenges, integrating SWOT and Porter's Five Forces analysis. It covers market segments by type, deployment mode, and application, and profiles key players like Illumina Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V., providing regional coverage and strategic takeaways for decision-makers.
Agilent Technologies (A) Valuation Check As New Biopharma Collaborations And Logic Analyzers Expand Growth Story
Agilent Technologies' new biopharma collaborations and logic analyzers offer fresh context for investors, despite recent share price dips. Analysts suggest the stock is undervalued at its current price of US$112.74, with a fair value estimated around $160.69, driven by strategic investments and recurring revenue streams. The article suggests investors consider both the optimism around its growth potential and cautious signals such as tariff pressures and tighter research budgets.
Insight Molecular Q1 2026 Earnings Call Transcript
Insight Molecular (NASDAQ: IMDX) held its Q1 2026 earnings call, detailing the submission of GraftAssuredX to the FDA in March 2026 and positive market research outcomes. The company projects Q2 2026 revenue of $250,000 and a high cash burn of over $9 million, expected to decrease in the latter half of the year. Key initiatives include expanding the Galactic Registry study, targeting regulatory compliance in Europe and the UK, and moving into heart transplant testing with the goal of long-term gross margins around 70%.
Agilent Technologies (A) Valuation Check As New Biopharma Collaborations And Logic Analyzers Expand Growth Story
Agilent Technologies (A) has been actively expanding its growth story through new biopharma collaborations and the launch of its 16850 Series portable logic analyzers. Despite recent share price easing, analysts' targets and intrinsic estimates suggest the stock is undervalued, with a fair value of $160.69 compared to the current $112.74. The company's strategic investments in higher-margin recurring revenue streams like consumables, software, and services are contributing to consistent growth and potential margin expansion.
Does Qiagen's (QGEN) Bigger Dividend and Governance Shift Signal a New Capital Allocation Playbook?
QIAGEN N.V. (QGEN) has proposed a 40% increase in its annual cash dividend and announced significant governance changes, including appointing a co-founder as Honorary Chairman, signaling a refreshed capital return framework. While these changes highlight a commitment to shareholder returns, the core investment narrative for QIAGEN still hinges on its molecular diagnostics and testing platforms driving earnings amid competitive and macro headwinds. The article emphasizes that operational risks and catalysts, like the expansion of the QuantiFERON franchise, remain key factors for the company's growth story.
Agilent Technologies Inc. stock (US00846U1016): Short interest rises amid market pressures
Short interest in Agilent Technologies Inc. (NYSE: A) increased by 7.64% to 4.82 million shares as of April 30, 2026, representing 1.71% of its public float. This rise comes as the stock has underperformed benchmarks, with a 0.99x return versus the S&P 500's 1.24x. Agilent, a leader in life sciences tools, maintains a strong market position despite these pressures but warrants continued monitoring by investors.
